PSC Biotech explains how increasingly complex CDMO networks create challenges for maintaining accurate, complete, and reliable pharmaceutical data across multiple organizations and systems. The article emphasizes strong data governance, quality agreements, risk-based audits, ALCOA++ principles, and clear responsibilities for data ownership, access, changes, and investigations. It also highlights digital tools such as electronic quality management systems, integrated data platforms, automated audit-trail monitoring, and real-time dashboards as ways to improve transparency, compliance, and inspection readiness across outsourced pharmaceutical operations.
